From 2014 says the jury is not in - Cure Parkinson's

Cure Parkinson's

25,550 members26,870 posts

From 2014 says the jury is not in

MBAnderson profile image
0 Replies

maybe somebody has something more recent or more authoritative?

" ... although there has been ongoing debate regarding the effect of L-dopa on neurons in PD patients. Some believe that treatment of PD patients with L-dopa potentially promotes neurodegeneration owing to the production of free radicals secondary to dopamine catabolism [31, 32], while others have found a potential neuroprotective effect in animal models [33, 34].

The ELLDOPA study was designed to try to determine whether L-dopa is toxic and accelerates the progression of PD [35]. Patients receiving L-dopa had less clinical deterioration from baseline than did placebo patients, suggesting a protective, rather than a toxic, effect. However, SPECT studies performed as part of this clinical trial demonstrated that patients who received L-dopa had an increased rate of decline in uptake of striatal β-CIT (a dopamine transporter ligand) compared with placebo, suggestive of a toxic, rather than a protective, effect. Therefore, the ELLDOPA study did not resolve the issue of whether or not L-dopa is toxic in PD [36]. Given the very robust beneficial effects of L-dopa for motor symptoms, the discrepant decline in imaging markers may be better explained by the artifactual effects on the ligands assessed (see below). The clinical effects of L-dopa are being studied currently in a delayed-start design (LEAP study) being conducted in the Netherlands (R. de Bie, personal communication) ... "

ncbi.nlm.nih.gov/pmc/articl...

Written by
MBAnderson profile image
MBAnderson
To view profiles and participate in discussions please or .
Read more about...

You may also like...

Benfotiamine (Fat Soluble Form Of Vitamin B1) and AD

less than the decline in the placebo arm (P = 0.0129) (66). ' ' Plasma measures from study...

5-HTP in patients not taking Sinemet can worsen symptoms of PD

in dopamine receptors is more severe. In PD, 5-HTP helps counteract negative effects that l-dopa in...

Phase 3 Positive Topline Results for Tavapadon

dyskinesia compared with placebo over 27 weeks Results demonstrate tavapadon’s potential to...

Eliminate Placebos To Encourage Participation

thousands of double blind studies making use of placebos to determine whether a particular drug or...

Patients with Parkinson’s disease (PD) report a strong craving for sweets

insulin on dopamine metabolism in patients with PD and how this could influence the potential...